Buccal Versus Vaginal Misoprostol in Surgical Termination of the First Trimester Missed Abortion in Erbil

Buccal Versus Vaginal Misoprostol for Cervical Ripening Prior to Surgical Termination of the First Trimester Missed Abortion in Erbil

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00892229

Enrollment

100

Registered

2009-05-04

Start date

2007-03-31

Completion date

2008-03-31

Last updated

2009-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Missed Abortion

Keywords

First trimester missed abortion, Misoprostol, buccal, vaginal, cervical ripening, first trimester, missed abortion

Brief summary

The purpose of this study is to determine the effectiveness of buccal misoprostol and comparing this with vaginal route of the same drug.

Interventions

DRUGMisoprostol (given buccally)

400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)

DRUGMisoprostol (given vaginally)

400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

19 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

* first trimester missed abortion

Exclusion criteria

* history or evidence of disorders that represent contraindication to the use of misoprostol: * severe pulmonary diseases * congenital or acquired heart diseases * glaucoma * prolonged use of corticosteroid * sickle cell anemia and adrenal insufficiency * smokers * known hypersensitivity to drugs * any evidence of infection * patient's refusal to participate in the study * patients with abnormal results of investigations * patients with previous operations on cervix like conisation, cauterization, previous dilatation and curettage * patients with complete abortion * patients with severe bleeding that required emergency surgical evacuation of the uterus * patients with partially dissolved tablets at the site of application in both groups

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of buccal administration to the more commonly vaginal route for preoperative cervical and priming in patients with first trimester surgical abortion. (Buccal Vs. Vaginal Misoprostol in the First Trimester Missed Abortion.)	March 2007 to March 2008

Secondary

Measure	Time frame
The secondary objectives are to compare the side effects and acceptability by the subjects.	March 2007 to March 2008

Countries

Iraq

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026